Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Charles Schwab Corporation Common Stock — how do they compare? ACADIA Pharmaceuticals Inc. trades at $28.43 (market cap $5.07B), while Charles Schwab Corporation Common Stock trades at $110.06 (market cap $189.09B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 37.3× ACADIA Pharmaceuticals Inc.'s market cap, and Charles Schwab Corporation Common Stock pays a 1.17% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | SCHW | |
|---|---|---|
Market Cap | $5.07B | $189.09B |
Sector | Health | Financials |
52-Week High | $29.45 | $110.06 |
52-Week Low | $20.06 | $85.35 |
Enterprise Value | $4.19B | — |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $28.38, down 3.5% over the past day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with $0.18 EPS versus $0.07 expected, and raised its 2026 revenue outlook. Revenue growth has accelerated from $517M in 2022 to $1.07B in 2025, with net income turning positive in 2024 and reaching $391M in 2025.
The outlook remains positive with 70% analyst buy ratings and a $33.89 consensus price target, though risks include high RSI levels suggesting overbought conditions and dependence on key drug trials. Near-term catalysts include Phase 2 data for remlifanserin in Alzheimer's psychosis, expected by October 2026.
Charles Schwab (SCHW) trades at $110.06, up 2.19% on the day, near its all-time high. The stock shows strong momentum with bullish technical signals and consistent earnings beats in recent quarters. Revenue grew to $23.92B in 2025 with a net income margin of 38.79%, while analyst consensus is a Buy with a $122.33 price target. Recent news highlights product expansion like Single Stock Futures and ongoing litigation matters.
Outlook remains positive driven by earnings growth and market position, but risks include legal challenges and interest rate sensitivity. The stock offers upside to analyst targets but faces overbought technical conditions near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
